Zhuoran Qiao has been awarded the inaugural Chen Institute and Science Prize for Al Accelerated Research for work critical to ...

(NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...

The Food and Drug Administration (FDA) has granted Priority Review to TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle invasive bladder ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...

Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that the U.S. Food and Drug Administration (FDA) accepted for review ...

SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) ...

The FDA clears GL-IL2-138, a groundbreaking oral drug modulating natural IL-2, set to revolutionize treatment in oncology.

The U.S. Food and Drug Administration's reviewers on Wednesday raised efficacy concerns over the use of Otsuka Pharma's drug ...